Exchange: NASDAQ·Updated 06:13 PM EDT
MAZE logo

MAZEMaze Therapeutics Inc.

$29.09
$0.72
(2.59%)
Today
Closed $28.53
$0.56
(1.96%)
After Hours
EarningsAug 12
Mkt Cap$1.54B
Vol231,106.00

About MAZE

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Connect Stocktwits to ChatGPT

New

Real-time sentiment, trending & news in ChatGPT

  • Sentiment
  • Watchers
  • Trending
  • News
Connect Plugin

Advertisement|Remove ads.